March 3, 2015
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Pfizer Inc. has licensed the Genedata Biologics™ enterprise platform for use at Pfizer biopharma research and development sites in the US and Europe. Genedata is supporting Pfizer’s global deployment and roll out project at Pfizer’s Global Biotherapeutic Technologies (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups.
“Pfizer is pleased to gain full access to this system for antibody discovery and protein engineering, which we hope will become part of Pfizer’s large-molecule discovery engine,” said Dr. Will Somers, VP of Global Biotherapeutic Technologies at Pfizer.
“Genedata Biologics helps increase biopharma research efficiency by integrating, in one single system, diverse antibody discovery workflows, and streamlining all molecular biology, expression, purification, and analytics processes,” said Dr. Othmar Pfannes, CEO of Genedata. “The platform flexibly addresses proprietary workflows and technologies as well as new requirements such as next-generation antibody formats and novel library technologies. All mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability can be managed by Genedata Biologics, which enables transparent decision-making on candidates to move forward with.”
“One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system,” said Dr. Sergio Rotstein, Director of Research Business Technology at Pfizer. “Genedata Biologics’ flexibility allows Pfizer to configure the system to address both proprietary discovery processes as well as Pfizer-specific business processes and nomenclature.”
“We are delighted to have Pfizer choose Genedata Biologics, another validation that our platform is increasingly recognized as the premier biologics R&D workflow system,” continued Dr. Pfannes. “Our partners are looking at our system to make their lead discovery and development process more efficient. Genedata Biologics enables true high throughputs in generating and validating candidates and we will continue to invest into Genedata Biologics to meet the rapidly growing demands in this exciting field.”
In the four short years since its release in 2011, Genedata Biologics has been rapidly adopted by more than a third of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations and technology transfer, to large, global, multi-site partnerships.